{"id":"NCT01431638","sponsor":"Novartis Pharmaceuticals","briefTitle":"Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients","officialTitle":"A 36-week Open-label Extension Study of CACZ885H2361 on the Safety and Tolerability of Canakinumab 150 mg s.c. Pre-filled Syringe (PFS) in Treating Acute Gouty Arthritis Flares in Frequently Flaring Patients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-08-25","primaryCompletion":"2013-05-09","completion":"2013-05-09","firstPosted":"2011-09-09","resultsPosted":"2021-07-19","lastUpdate":"2021-07-19"},"enrollment":397,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Acute Gouty Arthritis"],"interventions":[{"type":"DRUG","name":"Canakinumab 150mg in prefilled syringe","otherNames":[]}],"arms":[{"label":"Canakinumab 150mg","type":"EXPERIMENTAL"}],"summary":"This is a 36 week open-label extension of the canakinumab pre-filled syringe study for safety and tolerability in patients who have frequent flares of acute gouty arthritis.","primaryOutcome":{"measure":"Number of Participants Who Reported Adverse Events","timeFrame":"From start of the core study (CACZ885H2361 [NCT01356602]) upto end of the current study (48 weeks)","effectByArm":[{"arm":"Canakinumab, Pre-filled Syringes (PFS)","deltaMin":78,"sd":null},{"arm":"Canakinumab, Lyophilizate (LYO)","deltaMin":65,"sd":null},{"arm":"Triamcinolone Acetonide","deltaMin":64,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":2},"locations":{"siteCount":68,"countries":["United States","Canada","Germany","Lithuania"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":133},"commonTop":["Hypertension","Upper respiratory tract infection"]}}